Navigation Links
Post-menopausal therapy to improve women's quality of life
Date:5/29/2008

The passing of time makes ovaries lose their ability to produce estrogens and progesterone, the hormones which regulate the menstrual cycle. In this stage, when menstruation cesses, there appear physical and psychical changes such as hot flushes, sweating, vaginal dryness, articulation and bone pain, headaches, insomnia, sadness, depression and loss of memory, known as climateric symptoms. In Spain, the average age for the cessation of the menstrual cycle is 50 years old. In the Western countries, about 17% of the population belongs to the post-menstrual group.

Against the discomfort derived from the cessation of menstruation, there are medical treatments which contribute to maintain the quality of life of women in the face of the described changes. One of the treatments proposed is the so-called Replacement Hormone Therapy (RHT).

Fears about this therapy have been erroneously exaggerated, attributing to it secondary effects such as weight gain, breast cancer and risk of a thromboembolic disease.

A study carried out at the University of Granada on more than 500 postmenopausal patients rationalizes the fears above mentioned; and it concludes recommending the use of the hormone therapy, if necessary, for at least five years, under periodic medical controls.

The study

The research work has been read as a doctoral thesis by Dr Otilia Ruth Gonzlez Vanegas, under the supervision of Dr Jos Luis Cuadros Lpez and Dr Rosa Mara Sabatel Lpez (Department of Medicine of the UGR, San Cecilio University Hospital) and Dr ngela Mara Cuadros Celorrio (Hospital of beda).

The work, entitled Five-year later assessment of the use of different models of Replacement Hormone Therapy (RHT) during post-menopause, started from the question: how long must RHT be used considering the beneficial and adverse effects". They studied the clinical histories of 534 women who, between 1989 and 2004, have attended periodically medical, laboratory a
'/>"/>

Contact: Dr. Otilia R. Gonzlez / JL Cuadros
l.iglesias.000@recol.es
34-958-244-054
Universidad de Granada
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. HIV therapy in pregnancy-data support WHO recommendations
3. Family-based treatment more effective than supportive psychotherapy in treating bulimia
4. Trial to Test Gene Therapy for Angina in Women
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Aromatherapy Gift Line Sheds Humorous Light on Modern Therapy
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
9. New Drug No Substitute for Standard Blood-Clot Therapy
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... Kids, parents and schools need to work together t... FRIDAY, Nov. 21 (HealthDay News) -- Behavior that...cognized as bullying. , And as mounting researc... the victim, mental-health professionals, schools,...th new ways to combat this threatening behavior. ...
(Date:11/21/2008)..., HOUSTON(Nov. 21, 2008)The University of Texas He...rogram, Training Excellence in Aging Studies (TEXA...through a prestigious $2 million award from the Do...atching funds., "This will allow us to teach geri...t junior medical student to practicing physicians....
(Date:11/21/2008)... TUCSON, Ariz., Nov. 21 ...C ) today announced that Craig A. Norris, the Comp... to the Company,s Board of,Directors. Mr. Norris...2008,resignation of Steven I. Geringer and return...serve on any committee of the Board. , Mr. ...
(Date:11/21/2008)... Trials showed Banzel proved effective against Len... (HealthDay News) -- A new drug called Banzel (ruf...tment for a severe form of epilepsy called Lennox-...ation announced Friday. , The approval was base...ncluded patients ages 4 to 30. Compared to patient...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...t the Shanghai Children’s Medical Center have succ...rare, well-developed third arm from a two-month-ol...t arms that had been laid across Liu Junjie's ches...is further up his shoulder. ‘We found the nerves ...
... Health Organisation has ruled out human-to-human ...esian nurses tending patients with the disease // ...he ability to spread more readily among humans. 'T...nurses provide reassuring evidence that the virus ...
... drug used to treat chronic myeloid leukemia has s...f patients with the cancer.// The National Institu...h regulates drug approvals in the UK had only want...s, but the drug has not proved itself in clinical ...
...ight is back on drugs and high life in Mumbai with...hospital, and Sahil Zarru, who is suspected to hav...arty circuit here. "Cocaine, ecstasy, acid and her...rugs,are a rage with the rich and the famous in Mu...
Other Medicine News:Health News:Drugs Part of Mumbai High Life 2
(Date:11/21/2008)...England, November 21 , ...an Committee for Medicinal Products for Human Use ...n for the approval of Enbrel(R),(etanercept) as a...,adolescents with severe plaque psoriasis. If appr...mmittee,s recommendation, Enbrel will become the,...
(Date:11/20/2008)... , , PHILADELPHIA, Nov. 20 /PRNewswire-Firs...unced that the United States Food and Drug Adminis...MACTA(R) (eltrombopag) for the treatment of thromb...thic) thrombocytopenic purpura (ITP) who have had ...oglobulins or splenectomy. The approval is a signi...
(Date:11/20/2008)...lif., Nov. 20 Duska Ther...nced today that it has submitted its,pivotal Phas...r a Special,Protocol Assessment (SPA) procedure w..., Subject to securing an agreement with the...tive, double-blind, placebo-controlled and randomi...
(Date:11/19/2008)...O, Nov. 19 Posit Science Corporati...the Society for Neuroscience,Annual Conference in...e,training may benefit Baby Boomers. The compute...m (TM) uses adaptive exercises that target auditor...ed to drive generalized,improvements in cognition...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pregnant mice block out unwelcome admirers to protect their pups 4122 1Pregnant mice block out unwelcome admirers to protect their pups 4122 2Capella University Launches Online PhD Specialization in Nursing Education 24214 1Capella University Launches Online PhD Specialization in Nursing Education 24214 2Capella University Launches Online PhD Specialization in Nursing Education 24214 3Incidence of Mantle Cell Lymphoma on Rise 24211 1Incidence of Mantle Cell Lymphoma on Rise 24211 2Breast Fed Babies Have Fewer GI Infections 24208 1Breast Fed Babies Have Fewer GI Infections 24208 2
...roach to Address Growing Problem of Antibiotic Res...ER, British Columbia, March 26, 2007 /PRNewswire/ ... IDR-1 is the first,immune system trigger to cure ...ccording to a paper published in the April 2007,is...ghlights the work of Inimex and its,co-founders Dr...
...rial Shows CRESTOR Slowed Progression Of Atheroscl...sease , LONDON, March 26, 2006-AstraZeneca today a... is the first study to show a,positive effect on a...id artery disease and at low risk of coronary hear...uvastatin) 40mg and presented at,56th Scientific S...
Other Medicine Technology:Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 3First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 4First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 5
Grafton DBM Matrix PLF is the first bone graft material designed specifically for posterolateral fusion procedures. Unique trough-like design allows for easy use with allograft/autograft bone. Demine
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%.
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%.
Inductive demineralized bone matrix and conductive cancellous chips. DBM and cancellous chips will be free of foreign matter. Demineralized bone matrix particle size is 125 to 1000 . Cancellous chip
Medicine Products: